William Blair analyst Myles Minter has maintained their bullish stance on NMRA stock, giving a Buy rating today.
Myles Minter has given his Buy rating due to a combination of factors related to Neumora Therapeutics, Inc.’s strategic adjustments and potential future prospects. The company has announced amendments to its KOASTAL-2 and KOASTAL-3 Phase III studies, which are crucial for the development of navacaprant for major depressive disorder. These changes include reducing the number of clinical sites to those with the highest expertise, partnering with reputable institutions for patient verification, and implementing a screening database to exclude professional patients.
These strategic moves are designed to optimize patient selection and enhance the reliability of the trial outcomes, addressing issues that led to the previous study’s shortcomings. With the resumption of the KOASTAL studies planned, and data expected in the first half of 2026, there is a clear pathway for potential NDA filing and subsequent market launch. Minter’s rating reflects confidence in Neumora’s ability to overcome past challenges and capitalize on these future opportunities.
According to TipRanks, Minter is a 4-star analyst with an average return of 6.5% and a 45.33% success rate. Minter covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, Verve Therapeutics, and Entrada Therapeutics Inc.
In another report released today, Stifel Nicolaus also maintained a Buy rating on the stock with a $6.00 price target.